Dopa Decarboxylase

Subscribe to Selected New Research on Dopa Decarboxylase

158 relevant articles (9 outcomes, 16 trials/studies) found for this Bio-Agent

Description: One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of Parkinson's disease. EC 4.1.1.28.

Also Known As:

Decarboxylase, Dopa

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Aromatic-L-Amino-Acid Decarboxylases: 88

Dopa Decarboxylase: 158

Papaver somniferum TyDC5 protein

Experts

1.	Li, Ming D: 2 articles (12/2006 - 06/2005)
2.	Ma, Jennie Z: 2 articles (12/2006 - 06/2005)
3.	Kruse, T A: 2 articles (02/2003 - 11/2001)
4.	Ewald, H: 2 articles (02/2003 - 11/2001)
5.	Mors, O: 2 articles (02/2003 - 11/2001)
6.	Blackwood, D: 2 articles (02/2003 - 11/2001)
7.	Muir, W: 2 articles (02/2003 - 11/2001)
8.	Murray, V: 2 articles (02/2003 - 11/2001)
9.	Børglum, A D: 2 articles (02/2003 - 11/2001)
10.	Yang, Zeng-Yue: 1 article (11/2007)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 02/01/1996 - "We performed dynamic PET studies with fluorodopa (FDOPA) in 9 normal volunteers and 16 patients with Parkinson's disease to investigate the applicability of dopa decarboxylase (DDC) activity measurements as useful markers of the parkinsonian disease process" 11/01/2001 - "Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase." 02/01/1996 - "Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease." 01/01/1993 - "For the caudate nucleus, the DOPA decarboxylase activity (k3D, k3), tissue slope-intercept plots (kr3, ks3); and striato-occipital ratio [R(T)] analyses significantly discriminated between the normal volunteers and the patients with Parkinson's disease (p < 0.005) [with least significance for k3 (p < 0.05)], while the plasma slope-intercept plot (K) failed to do so" 09/01/1978 - "Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease." Get all the results and reference details, order at left...
2.	Parkinsonian Disorders (Parkinsonism) 03/01/1981 - "Levodopa with or without dopa decarboxylase is not a cure for parkinsonism" 01/01/1985 - "Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition." 12/01/1984 - "Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism." 07/01/1981 - "L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?" 11/16/1979 - "Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor]" Get all the results and reference details, order at left...
3.	Neuroblastoma 02/17/1978 - "There was significant antitumor activity against the neuroblastoma, which was enhanced by combination with a dopa decarboxylase inhibitor, Ro4-4602" 01/01/1985 - "Using the neuroblastoma clone N1E-115 which lacks DOPA decarboxylase and thus contains only low levels of dopamine the site of action of certain drugs could be determined" 07/01/1999 - "Of the 29 non-neuroblastoma tumor samples examined, the only tumor samples that expressed clearly detectable levels of both tyrosine hydroxylase and dopa decarboxylase were phaeochromocytomas" 06/01/1995 - "3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma." 01/01/1983 - "In three patients with neuroblastoma and high circulating levels of dopamine and dopa, we interfered pharmacologically with catecholamine biosynthesis either at the tyrosine hydroxylase or dopa decarboxylase step in an attempt to 1) improve the efficacy of antitumor therapy and 2) avoid the potential arrythmogenic interaction between elevated circulating catecholamines and an halogenated hydrocarbon anesthetic during surgery" Get all the results and reference details, order at left...
4.	Orthostatic Hypotension (Postural Hypotension) 06/01/1990 - "Treatment of both patients with the synthetic amino acid, d-l-threo-dihydroxyphenylserine, which contains a hydroxyl group and is converted to noradrenaline by dopa-decarboxylase, reduced symptoms and signs of postural hypotension and increased levels of plasma noradrenaline and its urinary metabolites" Get all the results and reference details, order at left...
5.	Neoplasms (Cancer) 06/01/1978 - "Pretreatment of animals bearing the S-91 Cloudman or ACI melanomas with Ro4-4602, a potent dopa decarboxylase inhibitor limited incorporation of label into adrenal tissue and enhanced entry of label into tumor" 04/01/2007 - "In addition, we found ATOH1 expression in 9 (16%) out of 56 analyzed adenocarcinomas and these tumors showed neuroendocrine features as shown by dopa decarboxylase mRNA expression and immunostaining for neuroendocrine markers" 07/01/1999 - "Of the 29 non-neuroblastoma tumor samples examined, the only tumor samples that expressed clearly detectable levels of both tyrosine hydroxylase and dopa decarboxylase were phaeochromocytomas" 12/01/1992 - "Factors which impair the prognosis of MTC are age (> 40 y), male sex, elevated DNA-content and mitotic activity of the tumor cells, immunoreactivity against dopa decarboxylase, histaminase and Leu-M1-antigen" 08/01/1985 - "We measured the activity of aromatic L-amino acid decarboxylase with L-dihydroxyphenylalanine as a substrate (DOPA decarboxylase) in normal lung tissues and lung tumors obtained fresh at surgery" Get all the results and reference details, order at left...
71 Diseases and 158 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	entacapone (Comtan)
3.	Dihydroxyphenylalanine (Dopa)
4.	Bromocriptine (Parlodel)
5.	Selegiline (E250)
6.	budipine
7.	Dopamine (Intropin)
8.	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)
9.	Norepinephrine (Noradrenaline)
10.	N-Methylaspartate (NMDA)
101 Drugs and Important Bio-Agents and 132 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Iridectomy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Infusion Pumps (Infusion Pump)
4 Therapies and Procedures and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>